sartorius stedim biotech

Adopting a Platform Approach to Upstream Processing Increases the Speed to Clinic of New Biopharmaceuticals

White Paper

turning science into solutions

Adopting a Platform Approach to Upstream Processing Increases the Speed to Clinic of New Biopharma-ceuticals

By Hugo DeWitt, Mitch Scanlan, Tim Ward and Christel Fenge

The biopharmaceutical market has enjoyed a significant expansion over the past few years. Around half of the world bestselling drugs are biologics and they account for around the same proportion of sales of the world's top one hundred drugs. Biopharmaceutical product pipelines are burgeoning not least because of the race to commercialise biosimilar products. These are products, marketed once patents on originator molecules have expired, that can bring the benefits of biologics to patients at significantly reduced costs (Dorey, 2014).

With large numbers of projects in their pipelines, biopharmaceutical companies must balance the commercial risks inherent in drug development with their need to control development costs while ensuring final manufacturing processes deliver the lowest Cost of Goods (CoGs). In 2004, the success rate for monoclonal antibodies from toxicological assessment through to launch was judged to be around 25% (Reichert & Pavlou, 2004). Our experience is that, a decade later, this success rate has dropped to around 10%. Companies must reach the clinic as quickly as possible to ensure they are not wasting budgets on products that will not succeed in patient trials.

Platform Approaches to Cell Line Development

One of the first steps in the journey of a product to the clinic is the development of a cell line for its expression. Companies can save around 3-6 months of development time by the adoption of a platform approach to cell line development. The Cellca CHO expression platform and development services allow companies to move from DNA to having a research cell bank and cell culture process much more quickly. Cellca adopt a process platform approach to process parameters, media and feeding strategy. The platform is highly robust and scale-up is straightforward. Among the antibody based biopharmaceuticals expressed by the platform are IgGs, Fc-fusion proteins, FAbs, bispecific-antibodies and biosimilar mAbs. Sartorius has generated extensive data to demonstrate the scalability of the Cellca CHO expression system in our BIOSTAT STR® bioreactor range from 50-L to 1000-L and in stirred-tank and rocking motion formats. Titers typically exceed 3 g/L and our results show protein concentrations as high as 9 g/L can be readily achieved (Figure 1).



Figure 1: Scalable, high-titer mAb process using the Cellca CHO expression system

Automated High Throughput Cell Culture Development Techniques

Automated high throughput process development will play a significant role in allowing companies to reach the clinic more quickly. Lonza Biologics, UK, showed that the ambr® 15 cell culture system could effectively rank CHO cell lines according to their specific productivity. The ranking was consistent with results from 10-L bioreactors (see Figure 2) but took much less time to perform.



Figure 2: ambr® 15 predicts the performance of clones at scale (data provided by courtesy of Lonza Biologics, UK)

Cobra Biologics found that the use of the ambr® 15 to replace 5-L bioreactor experiments could reduce parameter optimization from 22 to 6 weeks. They were able to perform more experiments with the same amount of resources (Lange et al., 2014). An American biopharmaceutical company we have worked with compared data on viable cell density, product accumulation and offline pH measurements and found good agreement between the ambr® 15 and the process operated at the 0.5-L, 2-L, 10-L, 100-L and 3000-L scales. Merck Research Laboratories have compared the ambr® 250 microbioreactor workstation to 1.5-L bioreactors for the performance of DOE experiments. They found the output to be comparable but the ambr® 250 to be more efficient at generating the data due to not having to perform certain blocking experiments (Bareither *et al.*, 2015).

Rapid Testing of Biosimilar Molecules

Biopharmaceutical companies are reducing the time it takes for products to reach the clinic still further by considering their approach to analytical testing and whether it can be outsourced (Monge & Hutchinson, 2016). By developing a suite of qualified off-the-shelf assays, that are ready for use on drug candidates, BioOutsource is reducing both the time taken and cost of developing biosimilars. Although by no means exhaustive list, Figure 3, indicates the type of characterization and compara-bility assays available for important innovator molecules biosimilar developers are targeting.

	Humira	Enbrel	Rituxan	Remicade	Herceptin	Avastin	Lucentis
Fc -RI by SPR Fc -RIIa by SPR Fc -RIIb by SPR Fc -RIIIa by SPR Fc -RIIIb by SPR FcRn by SPR	✓	✓	✓	✓	✓	✓	N/A
C1q by ELISA	✓	✓	✓	✓	✓	✓	N/A
Target binding	✓	✓	✓	✓	✓	✓	✓
ADCC	✓	✓	✓	✓	✓	✓	N/A
CDC	✓	✓	✓	✓	✓	✓	N/A
Potency assays	✓	✓	✓	✓	(✓)	✓	✓

Figure 3: Assays for the biosimilar characterization and comparability from BioOutsource

Increasing Speed to Clinic

Biopharmaceutical companies are reducing the time it takes for their products to reach the clinic by adopting platform processes, using high-throughput process development technologies and outsourcing activities that are not core competencies. In doing so, these organizations increase their competitiveness by ensuring they allocate their resources to those projects in their pipeline that have the greatest chance or reaching the market. Every month that a company can save during development translates to millions of dollars in additional revenues generated by the drug being on the market earlier.

An even bigger challenge, however, is not simply reaching the market more quickly, but doing so with a highly productive upstream process that is robust and delivers product with the required quality attributes. Sartorius is leveraging all of its experience in cell culture and single-use equipment to address this challenge. We have connected our leading upstream technologies and services to create an integrated platform from which the industry can work to deliver safer and cheaper medicines to patients in the shortest possible time.

References

Bareither, R., Goldfeld, M., Kistler, C., Tait, A., Bargh, N., Oakeshott, R., O'Neill, K., Hoshan, L. & Pollard, D. (2015) Automated disposable small-scale bioreactor for high-throughput process development: implication of the 24 bioreactor array. Pharmaceutical Bioprocessing. June 2015. 3(3). p185-197.

Dorey, E. (2014) How the biologics landscape is evolving. Clinical Pharmacist. Nov 2014. 6(9) Online | DOI: 10.1211/CP.2014.20067091

Lange, I., Chhartre, S. & Zoro, B. (2014) Reducing Timelines in Early Process Development – Using a Multiparametric Clone-Selection and Feed-Optimization Strategy. Bioprocess International 12(10).

Monge, M. & Hutchinson, N (2016) Single-Use Platforms Helping Democratize Biomanufacturing. Outsourced Pharma. May 2016. Online. Available at; http://www.outsourcedpharma.com/doc/singleuse-platforms-helping-democratize-biomanufacturing-0001 Accessed on; 18 May 2016.

Reichert, J. & Pavlou, A. (2004) Monoclonal antibodies market. Nature Reviews Drug Discovery. 3. p383-384. DOI:10.1038/nrd1386

Sales and Service Contacts

For further contacts, visit www.sartorius-stedim.com

Europe

Germany
Sartorius Stedim Biotech GmbH
August-Spindler-Strasse 11
37079 Goettingen

Phone +49.551.308.0
Fax +49.551.308.3289

Sartorius Stedim Systems GmbH
Robert-Bosch-Strasse 5 – 7
34302 Guxhagen

Phone +49.5665.407.0
Fax +49.5665.407.2200

France
Sartorius Stedim FMT S.A.S.
ZI des Paluds
Avenue de Jouques – CS 91051
13781 Aubagne Cedex

Phone +33.442.845600
Fax +33.442.845619

Sartorius Stedim France SAS
ZI des Paluds
Avenue de Jouques – CS 71058
13781 Aubagne Cedex

Phone +33.442.845600
Fax +33.442.846545

Austria
Sartorius Stedim Austria GmbH
Modecenterstrasse 22
1030 Vienna

Phone +43.1.7965763.18
Fax +43.1.796576344

Belgium
Sartorius Stedim Belgium N.V.
Rue Colonel Bourg 105
1030 Bruxelles

Phone +32.2.756.06.80
Fax +32.2.756.06.81

Hungary
Sartorius Stedim Hungária Kft.
Kagyló u. 5
2092 Budakeszi

Phone +36.23.457.227
Fax +36.23.457.147

Italy
Sartorius Stedim Italy S.r.l.
Via dell'Antella, 76/A
50012 Antella-Bagno a Ripoli (FI)

Phone +39.055.63.40.41
Fax +39.055.63.40.526

Netherlands
Sartorius Stedim Netherlands B.V.

Phone +31.30.60.25.080
Fax +31.30.60.25.099

filtratie.nederland@sartorius-stedim.com

Poland
Sartorius Stedim Poland Sp. z o.o.
ul. Wrzesinska 70
62-025 Kostrzyn

Phone +48.61.647.38.40
Fax +48.61.879.25.04

Russian Federation
LLC "Sartorius Stedim RUS"
Uralskaya str. 4, Lit. B
199155 St. Petersburg

Phone +7.812.327.53.27
Fax +7.812.327.53.23

Spain
Sartorius Stedim Spain, S.A.U.
Avda. de la Industria, 32
Edificio PAYMA
28108 Alcobendas (Madrid)

Phone +34.913.586.098
Fax +34.913.589.623

Switzerland
Sartorius Stedim Switzerland AG
Ringstrasse 24 a
8317 Tagelswangen

Phone +41.52.354.36.36
Fax +41.52.354.36.46

U.K.
Sartorius Stedim UK Ltd.
Longmead Business Centre
Blenheim Road, Epsom
Surrey KT19 9 QQ

Phone +44.1372.737159
Fax +44.1372.726171

Ukraine
LLS "Sartorius RUS"
Post Box 440 "B"
01001 Kiev, Ukraine

Phone +380.44.411.4918
Fax +380.50.623.3162

Americas

USA
Sartorius Stedim North America Inc.
5 Orville Drive, Suite 200
Bohemia, NY 11716

Toll-Free +1.800.368.7178
Fax +1.631.254.4253

Argentina
Sartorius Argentina S.A.
Int. A. Ávalos 4251
B1605ECS Munro
Buenos Aires

Phone +54.11.4721.0505
Fax +54.11.4762.2333

Brazil
Sartorius do Brasil Ltda
Avenida Senador Vergueiro 2962
São Bernardo do Campo
CEP 09600-000 - SP- Brasil

Phone +55.11.4362.8900
Fax +55.11.4362.8901

Mexico
Sartorius de México, S.A. de C.V.
Libramiento Norte de Tepotzotlan s/n,
Colonia Barrio Tlacateco,
Municipio de Tepotzotlan,
Estado de México,
C.P. 54605

Phone +52.55.5562.1102
Fax +52.55.5562.2942

leadsmex@sartorius.com

Peru
Sartorius Peru S.A.C.
Av. Emilio Cavenecia 264 San Isidro
15073 Lima, Perú

Phone +51.1.441 0158
Fax +51.1.422 6100

Asia | Pacific

Australia
Sartorius Stedim Australia Pty. Ltd.
Unit 5, 7-11 Rodeo Drive
Dandenong South Vic 3175

Phone +61.3.8762.1800
Fax +61.3.8762.1828

China
Sartorius Stedim Biotech (Beijing) Co. Ltd.
No. 33 Yu'an Road
Airport Industrial Park Zone B
Shunyi District, Beijing 101300

Phone +86.10.80426516
Fax +86.10.80426580

Sartorius Stedim (Shanghai)
Trading Co., Ltd.
3rd Floor, North Wing, Tower 1
No. 4560 Jinke Road
Zhangjiang Hi-Tech Park
Pudong District
Shanghai 201210, P.R. China

Phone +86.21.6878.2300
Fax +86.21.6878.2882

Sartorius Stedim Biotech (Beijing) Co. Ltd.
Guangzhou Representative Office
Unit K, Building 23
Huihua Commerce & Trade Building
No. 80 Xianlie Middle Road
Guangzhou 510070

Phone +86.20.37618687 | 37618651
Fax +86.20.37619051

India
Sartorius Stedim India Pvt. Ltd.
#69/2-69/3, NH 48, Jakkasandra
Nelamangala Tq
562 123 Bangalore, India

Phone +91.80.4350.5250
Fax +91.80.4350.5253

Japan
Sartorius Stedim Japan K.K.
4th Fl., Daiwa Shinagawa North Bldg.
8-11, Kita-Shinagawa 1-chome
Shinagawa-ku, Tokyo, 140-0001 Japan

Phone +81.3.4331.4300
Fax +81.3.4331.4301

Malaysia
Sartorius Stedim Malaysia Sdn. Bhd.
Lot L3-E-3B, Enterprise 4
Technology Park Malaysia
Bukit Jalil
57000 Kuala Lumpur, Malaysia

Phone +60.3.8996.0622
Fax +60.3.8996.0755

Singapore
Sartorius Stedim Singapore Pte. Ltd.
1 Science Park Road,
The Capricorn, #05-08A,
Singapore Science Park II
Singapore 117528

Phone +65.6872.3966
Fax +65.6778.2494

South Korea
Sartorius Korea Biotech Co., Ltd.
8th Floor, Solid Space B/D,
PanGyoYeok-Ro 220, BunDang-Gu
SeongNam-Si, GyeongGi-Do, 463-400

Phone +82.31.622.5700
Fax +82.31.622.5799

www.sartorius-stedim.com

Publication No.: S--4004-e160901 · Order No.: 85037-556-06 · Ver. 09 | 2016